

# Third Annual Hematologic Malignancy Symposium

**SATURDAY, MARCH 13, 2021**

**Morning sessions**

8 am – 8:05am	Welcome by symposium chairs & co-chairs
<i>Molecular Basis of Clonal Hematopoiesis</i>	
8:05am – 8:25am	<b>Infection as a Driver of Dnmt3a-Loss of Function Clonal Hematopoiesis</b> Speaker: <i>Katherine Y. King MD, PhD</i> <i>Baylor College of Medicine, Houston, TX</i>
8:30am – 8:50am	<b>FEATURED LECTURE</b> <b>Evaluating mutations in healthy blood</b> Speaker: <i>Caroline Watson, MD, PhD</i> <i>University of Cambridge, Cambridge, UK.</i>
8:55am – 9:15am	<b>Bone marrow failure in the elderly : from autoimmunity to clonality</b> Speaker: <i>Phillip Scheinberg, MD</i> <i>Hospital A Beneficência Portuguesa de São Paulo, São Paulo, Brazil</i>
<i>Myelodysplasia and Chronic Myelomonocytic Leukemia</i>	
9:20am – 9:40am	<b>Case based lecture on - Novel agents for LR-MDS</b> Speaker: <i>Guillermo Garcia Manero, MD</i> <i>MD Anderson Cancer Center, Houston, TX</i>
9:45am – 10:05am	<b>Understanding adaptive mechanism(s) of hypomethylating agents resistance</b> Speaker: <i>Hetty Carraway, MD, MBA, FACP</i> <i>Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH</i>
10:10am – 10:30am	<b>IDH inhibitors in myelodysplasia ?</b> Speaker: <i>Andrew H. Wei, MBBS, PhD</i> <i>The Alfred Hospital, Melbourne, AUS</i>
10:35am – 10:55am	<b>Chronic myelomonocytic leukemia (CMML) - Prime time for genomic driven management and Classification?</b> Speaker: <i>Eric Padron, MD</i> <i>Lee Moffitt Cancer Center, Tampa Bay, FL</i>

**BREAK**

## *Acute Myelogenous Leukemia - Myeloid Directed Therapy*

11:20am - 11:40am **FLT3 Mutated AML: current management**  
Speaker: *Alexander E. Perl, MD*  
*University of Pennsylvania, Perelman Center for Advanced Medicine*  
*Philadelphia, PA*

11:45am - 12:05pm **Targeting BCL-2 in AML**  
Speaker: *Daniel A. Pollyea, MD, MS*  
*University of Colorado School of Medicine, Denver, CO*

12:10pm - 12:30pm **P53 directed myeloid therapies**  
Speaker: *David A. Sallman, MD*  
*Lee Moffitt Cancer Center, Tampa Bay, FL*

### **BREAK** **POSTER EXHIBITS - POSTER PRESENTATION**

1:15pm - 1:35pm **Role of IDH inhibition in AML??**  
Speaker: *Courtney DiNardo, MD*  
*MD Anderson Cancer Center, Houston, TX*

## *Acute Myelogenous Leukemia - State-of-the-Art Lectures*

1:40pm - 2 pm **Post induction hypomethylating agents - insight from RELAZA trial**  
Speaker: *Uwe Platzbecker, MD*  
*University Hospital, Leipzig, Germany*

2:05pm - 2:25pm **How to overcome FLT3 inhibition resistance?**  
Speaker: *Mark Levis, MD, PhD*  
*Johns Hopkins University, Baltimore, MD*

2:30pm - 2:50pm **How do I treat elderly AML patients?**  
Speaker: *Gail J. Roboz, MD*  
*Weill Cornell Medical College, New York, NY*

### **BREAK**

3:15pm - 3:35pm **Panel discussion - Prime time - post induction AML maintenance, HMA vs targeted therapy or both?**  
  
*Mark Levis, MD, PhD*  
*Guillermo Garcia Manero, MD*  
*Gustavo Rivero, MD*  
*David A. Sallman, MD*

3:40pm - 4 pm **Closing remarks - abstracts winners and 4<sup>th</sup> symposium announcements**